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Summary The murine monoclonal antibody H17E2 recognises placental alkaline phosphatase (PLAP), an
antigen present in the human term placenta and also expressed by many tumours. The antibody is of value in
both immunoscintigraphy and radioimmunotherapy in testicular and ovarian cancer.
The small size of genetically engineered single chain antibodies (SCAs) should give diagnostic and
therapeutic advantages of improved tumour penetration and increased blood clearance compared to IgG.
Employing recombinant DNA techniques a SCA based on H17E2 has been expressed in Escherichia coli and
has been shown to bind placental alkaline phosphatase specifically.
When administered to nude mice bearing human tumour xenografts, the H17E2 SCA effectively localised to
tumour whilst a co-administered non-specific SCA did not. H17E2 SCA achieves tumour:blood ratios that are
superior to those achieved with whole IgG, probably owing to its rapid blood clearance.
We conclude that the H17E2 SCA is suitable for further investigation as an agent for clinical imaging and
therapy. Additionally, the SCA can also be used for the construction of antibody based fusion proteins to
target other effector functions to tumour cells.
Radiolabelled monoclonal antibodies have been investigated
by many centres for the experimental diagnosis and treat-
ment of malignant disease (Maraveyas & Epenetos, 1991).
However the properties of murine IgG result in several diag-
nostic and therapeutic problems. The relatively large size of
an IgG antibody (- 150 kDa) can be a factor in limiting
penetration into tumours, leading to areas of sub-optimal
uptake (Jain, 1990). The long serum half life (3-5 days,
Stewart et al., 1989) of radiolabelled intravenously admin-
istered monoclonal antibody can result in nontarget tissues,
particularly the bone marrow, receiving toxic doses of radia-
tion (Epenetos et al., 1986; Vaughan et al., 1987). Prolonged
blood residence also reduces the tumour:blood ratio thus
limiting the imaging information available. A further clinical
problem is that of immunogenicity. Repeated administrations
of murine monoclonal antibody often lead to patients mak-
ing an antibody response, generating human anti-mouse
antibodies (HAMA) (Schroff et al., 1985). This HAMA res-
ponse leads to rapid clearance of subsequent antibody ad-
ministrations, with immune complex formation and the risk
of anaphylaxis (Courtenay-Luck et al., 1986).
Univalent Fab and bivalent F(ab')2 antibody fragments
produced by proteolysis of antibody show increased tumour
penetrance, clear more rapidly (Kennel et al., 1991) but
remain immunogenic, can accumulate in the kidney and are
difficult to produce (Milenic et al., 1989). Single chain
antibodies (SCAs), each comprising one variable heavy- and
one variable light-chain domain ofimmunoglobulin joined by
a polypeptide linker, provide an alternative approach to
antibody miniaturisation (Huston et al., 1988). In addition to
their small size (25-30 kDa) SCAs have a number of advan-
tages over IgG. They can be produced economically in
bacteria, their specificity can be selected by in vitro 'immu-
nisation' (Marks et al., 1991) and they can be manipulated
by genetic engineering to form anti-tumour fusion proteins
incorporating additional effector functions (Chaudary et al.,
1989; Savage et al., 1993).
The anti-PLAP murine monoclonal antibody H17E2 re-
cognises the tumour associated antigen placental alkaline
phosphatase which is expressed in a large number of cases of
testicular and ovarian cancers (Travers & Bodmer, 1984;
Epenetos et al., 1984). It shows no cross-reactivity with
human liver and intestinal alkaline phosphatases, allowing it
to be used effectively in both immunoscintigraphy and rad-
ioimmunotherapy (Epenetos et al., 1985, 1986). In an effort
to avoid the HAMA response H17E2 has been 'reshaped' by
grafting its CDRs onto human framework regions (Ver-
hoeyen et al., 1991). This antibody, Hu2PLAP, has demon-
strated clinical benefits in early trials (Hird et al., 1991).
We describe here the construction, expression, and charac-
terisation of a single chain antibody based on the murine
monoclonal antibody H17E2 and report early preclinical in
vivo results in nude mice bearing human xenografts.
Materials and methods
Plasmid construction
The cDNA sequences encoding the VH and Vk domains were
cloned from the hybridoma secreting monoclonal antibody
H17E2, and were used to replace the corresponding VH and
VK sequences in pSW2, a plasmid designed for expression of
the Fv derivative of the anti-hen egg lysozyme antibody D1.3
(Ward et al., 1989), yielding the plasmid pFvPLAP. A
bacterial colony transformed with pFvPLAP was boiled in
500 fl of water for 5 min. A sample (5 .LI) of the cleared
supernatant was subjected to 30 rounds (94°C, 1 min; 55°C,
1 min; and 72°C, 1 min) of polymerase chain reaction (PCR)-
mediated amplification using VH1 and VK1 oligonucleotide
primers (Orlandi et al., 1989), using a PEC amplitaq kit.
Reaction products were digested with appropriate restriction
enzymes, gel-purified and the VH and VK fragments were
cloned into the appropriate sites of the plasmid
pSWsFvD 1.3myc (McCafferty et al., 1990). These regions
were sequenced in a number of the progeny plasmids, and
one with the expected sequence was designated
pSH17E2.2myc. This encodes a SCA derived from H17E2
under the transcriptional control of the lac promoter. Since
H17E2 SCA retains the c-myc antigenic tag derived from
pSWsFvD1.3myc, it can be detected with the antibody 9E10
(Evan et al., 1985).
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Expression andpurification ofHI7E2 SCA
A 500 ml culture of E. coli KS476 (Stauch et al., 1989)
transformed with plasmid pSH17E2.2myc was grown and
expression of H17E2 SCA was induced as previously des-
cribed (Ward et al., 1989). No biological activity of H17E2
SCA was detected in culture supernatants, and the c-myc
antigenic tag used for SCA recognition could only be de-
tected in the cell pellets (not shown). To produce functional
SCA a refolding protocol was employed (George et al.,
1993). Briefly, after pelleting, cells were disrupted by sonica-
tion and resuspended in 50 ml of 8 M urea. Insoluble material
was removed by centrifugation and the soluble material
dialysed against 0.1 M Tris base, 2 mM EDTA, 0.4 M arginine,
pH 8.0. Insoluble material produced during dialysis was
removed by centrifugation and the solution was then dialysed
exhaustively against PBS.
Affinity purification of the refolded material was per-
formed on PLAP (Calzyme, San Luis Calif.) immobilised on
a Carbolink (Pierce, Rockford IL. USA) column. Crude
refolded material was passed down the column under gravity
at 4°C. After washing with PBS, the bound protein was
eluted with 50 mM unbuffered diethylamine. Elution fractions
were immediately neutralised with 1/10 volume 1 mM Tris-
HCI pH 7.5, and then dialysed against PBS and stored at
4°C.
PLAP binding assay, ELISA, SDS-PAGE and Western blot
Biotinylated H17E2 antibodies were immobilised on strep-
tavidin-coated nylon pegs by incubation of the pegs in biotin-
H17E2 solution for I h at room temperature. The pegs were
rinsed in water and then placed in wells of a microtitre plate
(Dynatech Immulon) predosed with PLAP and either com-
peting SCA preparation or intact unlabelled HI7E2 IgG. In
the absence of these competing molecules, PLAP bound to
the pegs via immobilised biotin-H 17E2. The level of this
binding could be assayed by the enzymatic activity of the
bound enzyme. With either the SCA or unlabelled H17E2
IgG present, the PLAP binding was reduced in proportion to
the concentration of the competing species. The competitive
binding step was continued for 1 h at room temperature,
then the pegs were washed to remove unbound PLAP.
Bound PLAP was assayed by incubating the pegs for 1 h in
microtitre plates containing 200gsI volumes of pNPP (I mg
ml-') in 2 M diethanolamine adjusted to pH 10.2. Substrate
conversion was determined in terms of absorbance at 408 nm
measured in Titertek MCC/340 plate reader.
Specific in vitro binding of the SCA to immobilised antigen
was also confirmed by ELISA. Performed essentially as des-
cribed previously (Savage et al., 1993) the plates were coated
with either 100 tg ml-' PLAP, or lysozyme, BSA, FCS,
insulin or milk powder at appropriate dilutions. Bound SCA
was detected via its myc peptide tail with mAb 9E10 (Evan et
al., 1985) and with HRP-conjugated anti-mouse antibody.
Analysis of SCA preparations was carried out by SDS-
PAGE (Laemmli, 1970) using a 15% gel with a 3% stack.
Coomassie blue staining was used for direct visualisation.
For western blotting, proteins were transferred electrophor-
etically to a nitrocellulose membrane and probed with mAb
9E10 using AP-conjugated anti-mouse antibodies (Promega)
for visualisation.
Radiolabelling and solidphase radioimmunoassay (RIA)
Samples of the SCAs H17E2 and TEL9 (gift of Dr T.
Bonnert), (Marks et al., 1992) were labelled with '25I and 1'3i
respectively using the lodogen method of Fraker and Speck
(1978). Unincorporated iodine was removed by gel filtration
on a G25 Sephadex column (Pharmacia). SCA-containing
fractions were pooled and the protein concentration and
specific activity were measured.
To estimate the antigen binding affinity of the labelled
SCA, a RIA and Scatchard analysis were used. Using 1001il
volumes throughout, flexible Titertek Elisa plates were coated
overnight at room temperature with 100 jig ml-' PLAP in
50 mM bicarbonate buffer, pH 9.6. After washing in PBS,
non-specific binding sites were blocked by incubation with a
1% solution of milk powder in PBS for 30 min at room
temperature. Dilutions of radiolabelled SCA were applied
and incubated for 1 h at room temperature. After further
washes in PBS, bound radioactivity was measured by cutting
out the individual wells and counting in a Minaxi 5550
gamma counter (Canberra Packard). Samples of the orginal
dilutions were also counted to determine the total of bound
and unbound counts at each dilution. To determine the
binding affinity calculations described by Scatchard (1949)
were performed.
In vivo pharmacokinetics
Tumour xenografts of the H.Ep-2 human epidermoid tumour
cell line (Toolan, 1954) were produced by subcutaneous
inoculation of female nude mice with 5 x 106 cells. After 3
weeks growth, when the tumours measured 6-8 mm in
diameter, 0.5giCi (0.5gig) of 251I-H17E2 SCA and '31I-TEL9
SCA were administered concurrently in 100 gl of PBS via a
lateral tail vein. In parallel, 5giCi of radiolabelled H17E2
IgG was injected into a similar group of mice. Mice were
sacrificed at 1, 3, 5, 24 and 48 h post-injection by cardiac
puncture and exsanguination. Samples of tumour and non-
target tissues were weighed and incorporated radioactivity
measured for both the 1251 and 131I content in a gamma
counter. Results are expressed as the percentage of injected
dose per gram of wet tissue (percentage ID g- ) and as
tumour:blood ratios.
Results
Expression, refolding andpurification ofSCA HI7E2
Since Hi 7E2 SCA was expressed as an insoluble protein in
E. coli, cells were sonicated, the sonicate was dissolved in 8 M
guanidine hydrochloride and after dialysis against 0.1 M Tris
base, 2 mM EDTA, 0.4 M arginine, pH 8.0 and then PBS, the
soluble fraction was applied to an affinity column containing
immobilised PLAP. Gel electrophoresis and Western blotting
showed this simple refolding protocol to be very inefficient
(Figure 1). Monoclonal antibody 9E10 (which recognises the
polypeptide myc tag fused at the carboxyl end of the SCA)
identified a single band at 30 kDa as expected. The material
eluted from the column was subjected to SDS-PAGE in
reducing conditions and then stained with Coomassie blue.
Figure 2 shows again the presence of a single band at
30 kDa. In this initial series of experiments no attempt was
made to optimise the yield of functional SCA and the total
yield of purified material was only 100gig.
Specificity andaffinity ofHI17E2 SCA
Specificity of H17E2 SCA was demonstrated by a competi-
tion assay in which affinity-purified refolded SCA was able to
inhibit competitively the binding of PLAP to immobilised
biotinylated parent antibody H17E2. A dose-dependent de-
crease in signal occurred with increasing concentration of
H17E2 SCA and with increasing concentrations of IgG
H17E2 (Figure 3). Neither non-refolded crude H17E2 SCA
(not shown) nor refolded anti-lysozyme SCA D1.3 had any
ability to inhibit the binding of parent IgG to PLAP. In
binding studies with a panel of different immobilised antigens
(PLAP, hen egg lysozyme, BSA, FCS, insulin and milk
powder), PLAP was the only material to which there was any
significant binding of the H17E2 SCA with no evidence of
any non-specific sticking to the panel of other antigens tested
(not shown).
When the results of the RIA (Figure 4) for the estimation
of the antigen binding affinity were subjected to Scatchard
analysis, they give a value for the association constant of at
least 10-8M.740 P. SAVAGE et al.
1 2 3 4 more rapid clearance from the circulation (Colcher et al.,
kDa 1990; Milenic et at., 1991). The studies described here
confirm that a functional SCA has been generated from the
variable domains of the anti-PLAP monoclonal antibody
H17E2. The SCA was successfully expressed in bacteria, but
46
- the biologically active form was only produced after the use
of a simple refolding protocol. The ability of this SCA to
specifically bind to PLAP is demonstrated through the com-
petitive binding studies with the parent IgG. The com-
parative binding studies with the panel of antigens indicates
that this SCA is free of the non-specific stickiness that can
undermine the usefulness of some recombinant antibody
30 - fragments (Ward et al., 1989).
>1-M)S The antigen binding affinity of this SCA
similar to those of other SCAs (Glockshuber et at., 1990;
Colcher et at., 1990) but is reduced from the measured
affinity of the parent IgG (M. Verhoeyen, unpub). This may
result from constraints of the SCA linker which may alter
slightly the native configuration of the antigen binding site.
In this initial study the total yield of purified material was
low, perhaps owing to the inefficiency of the simple refolding
protocol used. This figure should be greatly improved by
optimising the refolding protocol (McCartney et at., 1991). It
should be possible to increase the final yield, as experience
with Fab fragment produced by bacterial fermentation indi-
cates that expression levels of over 500 mg L can be
achieved (Better et at., 1990).
1 2 3
15- l l l-kDa
1, D1.3 SCA; lane 2, crude unfolded H17E2 SA loaded onto the 50
-
affinity column; lane 3, material flowing through the affinity 50
column; and lane 4, affinity-purified material eluted from the
column.
In vivo pharmacokinetics
Figure 5 shows tumour:blood ratios obtained with the
Hi7E2 SCA and the non-specific TEL 9 SA, compared to
those obtained with the HI7E2 IgG. Tumour:blood ratios
superior to those attained with whole IgG were obtained 25-
with specific SCA, and these improved ratios were achieved
at earlier times. Neither the IgG nor the non-specific SCA
gave a tumour:blood ratio greater than 1, but the Hi17E2
SCA gave values above this early as 24 h and further im-
proved values at 48 h post-injection. This early improvement
in tumour:blood ratio may significantly improve the clinical
practicalities of antibody imaging. Values for the absolute
uptake of SCAs and IgG are given in Table 1. Although use
of Hi17E2 SCA gives improved ratios, it gives relatively low
absolute uptake when administered as a single intravenous 15-
bolus. The serum half life for the SCAs and the IgG were
calculated. Specific and non-specific SCA both exhibit rapid
clearance with a T1/2P of 1.8 and 2.1 h respectively com-
pared to prolonged residence of the IgG (TI/2p = 141 h).
Discussion _1
In addition to their low cost of production and ease of
manipulation, single chain antibodies offer a number of
theoretical advances over IgG for in vivo applications. These Figure 2 Coomassie stained gel of affinity-purified material, lane
advantages result from the smaller size of the SCA that lead 1, H17E2 SCA; lane 2, molecular weight markers; and lane 3,
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Figure 3 Effects of competing H 17E2 IgG, affinity-purified H17E2 SCA and non-specific anti-lysozyme D1.3 SCA on inhibition of
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Figure 4 Scatchard plot of the radioimmunoassay measuring
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Figure 5 Pharmacokinetics of H17E2 SCA and IgG and the
non-specific SCA Tel 9 in tumour bearing nude mice. Results are
expressed as tumour:blood ratios. Means and standard deviations
of triplicate data-points are given.
In vivao, H 17E2 SCA localised to the tumour bearing
tumour associated antigens in marked contrast to non-
specific TEL9 SCA, a result in agreement with previous
reports of successful in x'iio localisation of anti-tumour SCAs
(Colcher et al., 1990).
This current work extends previous studies: here the ob-
served binding is shown to be through specific uptake as
there is no significant tumour binding of the non-specific
SCA TEL9. This study is the first to compare the binding of
concurrently administered specific and non-specific SCAs.
Tumour:blood ratios achieved with use of a specific SCA are
significantly improved over those from use of whole IgG and
are observed much earlier. These results with the H 17E2
SCA given tumour/blood values less than those reported with
some other SCA preclinical studies. The potential reason for
these discrepancies include; the relatively poor vascularity of
H-ep 2 tumours in mice, the presence of circulating PLAP
shed from the tumour and the fact that this SCA has not
been optimised regarding its charge for optimal tumour
penetrance. However these early good ratios should be of
considerable benefit in imaging and potential therapy, with
improved and earlier definition occurring. The rapid blood
clearance noted in previous reports on SCA kinetics is
confirmed here. Although tumour:blood ratios obtained with
specific SCA are superior to those seen with IgG, the levels
of absolute uptake are lower. This poses a potential difficulty
for the use of radioimmunotherapy with SCAs. Optimisation
of administration methods may overcome this. A steady state
produced by continuous infusion over a longer period might
result in higher absolute tumour levels. With the rapid renal
clearance of the iodinated SCA it should be possible to
control the levels very accurately to achieve maximal tumour
uptake, while keeping the serum level below the threshold for
nontarget toxicity. As shown here, administration by bolus
injection does not seem the optimal way to achieve thera-
peutic doses to a tumour. Another difficulty relates to the
potential immunogenicity of the SCA, particularly of the
linker sequence. This might be minimised by sequential use
of SCAs with different linker sequences, a number of which
have already been shown to be equally effective in producing
functional molecules.
In summary the H 17E2 SCA selectively binds antigen-
positive tumour cells in vivO, and shows favourable phar-
macokinetic behaviour for therapy and localisation. It is
therefore an attractive candidate for a SCA-based fusion
proteins (Chaudary Ct al., 1989; Savage et al., 1993) to target
other effector functions to tumour cells.
Table I Tumour uptake and pharmacokinetics of specific (H17E2)
and control (TEL9) single chain antibodies and H17E2 IgG. Means
and standard deviations of triplicate data-points are given
Tumouir luptake ( % ID/g)
Tim7?e (h) Hl7E2 SCA TEL9 SCA H17E2 IgG
1 2.2+0.4 2.2+0.2 ND
3 1.4 +0.2 1.6 +0.4 ND
5 0.7 0.2 0.9 +0.4 ND
24 0.15 ± 0.04 0.08 ± 0.02 7.7 ± 1.1
48 0.18 ± 0.07 0.08 ± 0.02 9.3 + 1.0
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